These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28729289)

  • 1. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.
    Wiebe C; Rush DN; Nevins TE; Birk PE; Blydt-Hansen T; Gibson IW; Goldberg A; Ho J; Karpinski M; Pochinco D; Sharma A; Storsley L; Matas AJ; Nickerson PW
    J Am Soc Nephrol; 2017 Nov; 28(11):3353-3362. PubMed ID: 28729289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients.
    Lee H; Min JW; Kang H; Lee H; Eum SH; Park Y; Yang CW; Chung BH; Oh EJ
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DR/DQ eplet mismatch predicts
    Wong ETY; Pochinco D; Vathsala A; Koh WK; Lim A; Sran HK; D'Costa MR; Chang ZY; Nickerson PW; Wiebe C
    Front Genet; 2024; 15():1447141. PubMed ID: 39262421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm.
    Bryan CF; Chadha V; Warady BA
    Pediatr Transplant; 2016 Nov; 20(7):926-930. PubMed ID: 27448994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DQ eplet mismatch load may identify kidney transplant patients eligible for tacrolimus withdrawal without donor-specific antibody formation after mesenchymal stromal cell therapy.
    Bezstarosti S; Meziyerh S; Reinders MEJ; Voogt-Bakker K; Groeneweg KE; Roelen DL; Kers J; de Fijter JW; Heidt S
    HLA; 2023 Jul; 102(1):3-12. PubMed ID: 36841928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
    Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
    Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation.
    Yanyiam P; Kantachuvesiri S; Thammanichanond D
    Transplant Proc; 2024 Apr; 56(3):515-520. PubMed ID: 38368130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA B eplet mismatches in the context of delayed graft function and low tacrolimus trough levels are risk factors influencing the generation of de novo donor-specific antibodies and acute rejection in the early stage after kidney transplantation.
    Gao S; Gong H; Li M; Lan P; Zhang M; Kuang P; Zhang Y; Hu X; Ding C; Li Y; Ding X; Xue W; Zheng J
    Transpl Immunol; 2023 Dec; 81():101955. PubMed ID: 37931666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch epitope load predicts de novo-DSA-free survival in pediatric liver transplantation.
    Shin S; Lee M; Dente E; Yazigi N; Khan KM; Kaufman SS; Ahn J; Timofeeva OA; Ekong UD
    Pediatr Transplant; 2022 Jun; 26(4):e14251. PubMed ID: 35279919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human leukocyte antigen epitope mismatch loads and the development of de novo donor-specific antibodies in cardiothoracic organ transplantation.
    Bedford A; Jervis S; Worthington J; Lowe M; Poulton K
    Int J Immunogenet; 2022 Feb; 49(1):30-38. PubMed ID: 34904369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients.
    Kishikawa H; Kinoshita T; Hashimoto M; Fukae S; Taniguchi A; Yamanaka K; Nakagawa M; Nishimura K
    Transplant Proc; 2018 Oct; 50(8):2388-2391. PubMed ID: 30316363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA class II eplet mismatch load improves prediction of dnDSA development after living donor kidney transplantation.
    Tafulo S; Malheiro J; Santos S; Dias L; Almeida M; Martins S; Pedroso S; Mendes C; Lobato L; Castro-Henriques A
    Int J Immunogenet; 2021 Feb; 48(1):1-7. PubMed ID: 33145950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity.
    Wiebe C; Kosmoliaptsis V; Pochinco D; Taylor CJ; Nickerson P
    Transplantation; 2018 Aug; 102(8):1338-1343. PubMed ID: 29443827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
    Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
    Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
    Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
    Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
    Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G
    Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients.
    Zhang X; Kransdorf E; Levine R; Patel JK; Kobashigawa JA
    Hum Immunol; 2020 Jul; 81(7):330-336. PubMed ID: 32307126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the level of HLA eplet mismatch a risk factor for graft loss among kidney transplant recipients who have already formed de novo donor specific antibody?
    Wen J; Basu A; Bentall A; Henderson N; Dukek B; Gandhi M; Schinstock C
    Hum Immunol; 2021 Apr; 82(4):240-246. PubMed ID: 33618904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients.
    Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J
    Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.